Zeitschrift für Phytotherapie 2022; 43(S 01): S54
DOI: 10.1055/s-0042-1749307
Abstracts Poster | Phytotherapie 2022 – innovativ

Comparison of epidemiological data on functional GI diseases under an herbal therapy from non-interventional studies in the US and Germany

O Kelber
1   Bayer Consumer Health, Innovation & Development, Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, 64295 Darmstadt, Germany
2   Kooperation Phytopharmaka GbR, 53173 Bonn, Germany
,
E Raskopf
3   Institut für Medizinische Statistik und Bioinformatik, Universitätsklinikum Köln, 50937 Köln, Germany
4   ClinCompetence Cologne GmbH, 50672 Köln, Germany
,
A Lindner
1   Bayer Consumer Health, Innovation & Development, Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, 64295 Darmstadt, Germany
,
J Möller
1   Bayer Consumer Health, Innovation & Development, Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, 64295 Darmstadt, Germany
,
K Nieber
2   Kooperation Phytopharmaka GbR, 53173 Bonn, Germany
5   Institute of Pharmacy, University of Leipzig, 04103 Leipzig, Germany
,
O Grundmann
6   College of Pharmacy, Department of Medicinal Chemistry, University of Florida, FL, 32610, USA
7   College of Nursing, Department of Biobehavioral Nursing Science, University of Florida, FL, 32610, USA
› Author Affiliations
› Further Information
 

Introduction The comparison of epidemiological data from different countries can help to improve the understanding of patient's needs and of therapeutic approaches globally. In two recent non-interventional studies (NIS), one from the US and the other from Germany [1] [2] [3], data from patients with functional GI symptoms using an herbal medicine have been collected. The US study was conducted by Grundmann et al. by an internet questionnaire. The study from Germany was a NIS in patients who used natural products (PhytoVIS) and carried out through interviews in pharmacies and doctor's offices.

Methods Original data on users of the same natural product, STW 5, were selected from both studies and evaluated using descriptive statistics.

Results The number of patients meeting the inclusion criteria in the US study was 50 resp. 1515 in the German one (DE). 88% of the US resp. 70% of DE participants were female. Dyspepsia-like symptoms were the largest group in both studies, while IBS could be assigned to 15.6% resp. 4.0% of patients. 50.7% resp. 63.1% rated the treatment very effective, 24.5% resp. 32.4% moderate, 5.9% resp. 5.6% not effective, and 21.7% resp. 0% did not know.

Discussion There are, accordingly, considerable similarities, e. g. in the predominance of female patients and the rating of the treatment effect. Overall, these studies turn out to be a valuable source of data on the use of an herbal treatment and for assessing differences and similarities between the patient populations in the US and Germany.

Acknowledgment The PhytoVIS study is supported by Kooperation Phytopharmaka GbR, Bonn, Germany.



Publication History

Article published online:
13 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Raskopf E. et al. Z Phytother 2017; 38 (Suppl. 01) S40-S41
    Article in Thieme ConnectPubMed
  • 2 Möller J. et al. Neurogastroenterol Motil 2019; S4: 32
    PubMed
  • 3 Grundmann O. et al. Comp Ther Med 2018; 41: 225-230
    PubMed